LncRNA growth arrest-specific 5 (GAS5) was originally discovered in growth-arrested cells [12] and has been reported to be involved in multiple diseases by regulating NF-κB pathway [13], cAMP/CREB pathway [14], Wnt/β-catenin pathway [15] and etc. We previously found that GAS5 was downregulated and associated with worse clinicopathological characteristics in NSCLC, and suppressed growth and migration of tumor cells by increasing p53 expression at post-transcription level [16]. The gene discussed is TP53; the disease is non-small cell lung carcinoma.